Incyclinide
Incyclinide
Incyclinide (pronounced in-sy-kli-nide) is a tetracycline derivative that was under development for the treatment of rosacea and acne. It was originally developed by CollaGenex Pharmaceuticals, but its development was discontinued in 2007.
Etymology
The term 'Incyclinide' is derived from the word 'tetracycline', a class of antibiotics to which it belongs. The prefix 'In-' is likely to denote its innovative or internal action, while '-cyclinide' is a common suffix for tetracycline derivatives.
Pharmacology
Incyclinide is a second-generation tetracycline derivative. It works by inhibiting the production of certain proteins that contribute to the inflammation and immune response associated with rosacea and acne. Unlike other tetracyclines, Incyclinide does not have antibiotic properties.
Clinical Trials
In 2006, Incyclinide entered Phase 3 clinical trials for the treatment of rosacea. However, the trials were discontinued in 2007 due to lack of efficacy.
Related Terms
- Tetracycline: A class of antibiotics that Incyclinide belongs to.
- Rosacea: A skin condition that Incyclinide was under development to treat.
- Acne: A skin condition that Incyclinide was under development to treat.
- CollaGenex Pharmaceuticals: The company that originally developed Incyclinide.
External links
- Medical encyclopedia article on Incyclinide
- Wikipedia's article - Incyclinide
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski